Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results
Matthew Butler, Mathieu Seynaeve, Abigail Bradley‐Westguard, Jianan Bao, Ania Crawshaw, Susannah Pick, Mark J. Edwards, Timothy R. Nicholson, James Rucker
The Journal of Neuropsychiatry and Clinical Neurosciences May 17, 2022 DOI: 10.1176/appi.neuropsych.21080213 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 1,048 |
| Population | People with functional neurological disorder (FND) recruited internationally through social media and patient groups |
| Duration | 1-month survey access period |
| Keywords | Psychoactive substance |
| Citations | 6 |
| Key findings | 46% of respondents had tried legal psychoactive substances for FND symptom management, and 15% had used illicit substances, with many willing to try medically supervised psychedelic therapy. |
Abstract
Objective: Functional neurological disorder (FND) causes a high burden of disability and distress. Although it is a common disorder, there is a pressing need for improved access to evidence-based treatments. With difficulties in finding effective treatment, some people with FND may seek alternative means of symptom relief, such as legal and illicit psychoactive substances, although the prevalence and nature of such self-management strategies are currently unclear. Additionally, psychoactive substances may represent novel treatment research opportunities, particularly for those with suboptimal improvement. The investigators examined the use of self-management techniques, as well as perspectives on novel therapies, in this patient population.
Methods: An online survey was created to assess self-management strategies and views on novel treatments for FND, including psychedelic therapy. The survey was accessible for 1 month, and respondents were recruited internationally through social media and patient groups. A total of 1,048 respondents from 16 countries completed the survey.
Results: Almost half (46%) of 980 respondents reported having tried legal psychoactive substances for the management of their FND symptoms and, on average, nicotine, alcohol, and cannabidiol were reported as modestly effective. Additionally, 15% of respondents reported having used illicit substances, mostly cannabis, to manage FND, with the majority reporting moderate effectiveness and experiencing no or minimal physical (90%) and psychological (95%) sequelae. Many respondents (46%) reported that they would be willing to try medically supervised psychedelic therapy (with 19% of respondents ambivalent) if it were found to be safe and effective.
Conclusions: Many people with FND seek alternative means of symptom management outside usual medical care, including legal and illicit psychoactive substances. Further research exploring novel treatment options, such as psychedelics, in FND may be warranted.
Citations in the library
Cited by 5
- Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020 Journal of Psychopharmacology March 6, 2023
- Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks. Journal of Psychopharmacology April 23, 2024
- Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol. Wellcome Open Research 2024
- Psilocybin and Motor Function: A Triple‐Blind, Dose‐Finding Study in Healthy Participants Psychiatric Research and Clinical Practice July 23, 2024
- Psychedelics in functional disorders: A scoping review Progress in Neuro-Psychopharmacology and Biological Psychiatry February 10, 2026
Cites 30
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder The Journal of Clinical Psychiatry November 15, 2006
and 25 more in the library